Immunogenicity of interferon-alpha2 in therapy: Structural and physiological aspects

Acta Virologica

Volumn 43, Issue 1, 1999, Pages 63-70

  Kontsek, P ^a   Liptakova H ^a   Kontsekova E ^b  

^a INSTITUTE OF VIROLOGY   (Slovakia)

^b Physics and Informatics   (Slovakia)

Author keywords

Antibodies; Immunogenicity; Recombinant interferon alpha2; Therapy

Indexed keywords

ALPHA2 INTERFERON; BEROFOR; INTERFERON ANTIBODY; LYMPHOBLAST INTERFERON; NEUTRALIZING ANTIBODY; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ALPHA2C INTERFERON; UNCLASSIFIED DRUG; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; EPITOPE; INTERFERON-ALPHA 2;

ANTIBODY RESPONSE; CANCER; CANCER IMMUNOTHERAPY; DRUG ANTIGENICITY; DRUG MANUFACTURE; DRUG STORAGE; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEIN CONFORMATION; PROTEIN TERTIARY STRUCTURE; REVIEW; VIRUS INFECTION; ANTIBIOTIC RESISTANCE; ANTIBODY PRODUCTION; CHEMISTRY; DRUG RESISTANCE; IMMUNOLOGY; PHYSIOLOGY;

ANTIBODY FORMATION; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, NEOPLASM; EPITOPES; HUMANS; INTERFERON-ALPHA; PROTEIN STRUCTURE, TERTIARY;

EID: 0032585852     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Adolf GR, Kalsner I, Ahorn H, Maurer-Fogy I, Cantell K (1991): Natural human interferon-α2 is O-glycosylated. Biochem. J. 276, 511-518.
2. Andersson G, Lundgren E, Ekre HPT (1991): Application of four anti-human interferon-α monoclonal antibodies for immunoassay and comparative analysis of natural interferon-a mixtures. J. Interferon Res. 11, 53-60.
3. Antonelli G (1997): In vivo development of antibody to interferon: an update to 1996. J. Interferon Cytokine Res. 17 (Suppl. 1), S39-S46.
4. Antonelli G, Currenti M, Turriziani O, Dianzani F (1991): Neutralising antibodies to interferon a: relative frequency in patients treated with different preparations. J. Infect. Dis. 163, 882-885.
5. Antonelli G, Currenti M, Turriziani O, Riva E, Dianzani F (1992): Relative frequency of nonneutralising antibodies to interferon (IFN) in hepatitis patients treated with different IFN-α preparations. J. Infect. Dis. 165, 593-594.
6. Bendtzen K, Svenson N, Jonsson V, Hippe E (1990): Autoantibodies to cytokines - friends or foes? Immunol. Today 11, 167-169.
7. Crowe JS, Gewert DR, Barber KA, Lewis AP, Sims MJ, Davies SL, Salom CL, Wood J, Thomas HC, Thursz M, Lok AS (1994): Interferon (IFN)-α2 genotype analysis of Chinese chronic hepatitis B patients undergoing recombinant IFN-α2a therapy. J. Infect. Dis. 169, 875-878.
8. Csabayová M, Kontseková E, Kontsek P (1995): Relativity of an antigenic homology between human interferon a1 and interferon-α2. Immunol. Invest. 24, 787-793.
9. Dianzani F, Antonelli G, Amicucci P, Cefaro A, Pintus C (1989): Low incidence of neutralising antibody formation to interferon-α2b in human recipients. J. Interferon Res. 9 (Suppl. 1), S33-S36.
10. Gabain von A, Lundgren E, Ohlsson M, Holmgren E, Josephsson S, Alkan SS (1990): Three human interferon-α2 subvariants disclose structural and functional differences. Eur. J. Biochem. 190, 257-261.
11. Galton JE, Bedeford P, Scott JE, Brand CM, Nethersell ABW (1989): Antibodies to lymphoblastoid interferon. Lancet 2, 572-573.
12. Gewert DR, Sharp NA, Barber KA, Cooper H, Tucher D, Lewis AP, Thursz M, Crowe JS (1995): Detection of rare allelic variants of the interferon-α2 gene in human genomic DNA. J. Interferon Cytokine Res. 15, 403-405.
13. Gutterman JU, Fine S, Quesada J, Horning SJ, Levine JF, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dziewanowski Z (1982): Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance and biologic effects in cancer patients. Ann. Intern. Med. 96, 546-556.
14. Figlin RA, Dekernion J, Mukamel E (1986): Recombinant leukocyte A interferon (rIFN-α2a) antibody development in advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 5, 222-229.
15. Hochuli E (1997): Interferon imunogenicity: technical evaluation of interferon α2a. J. Interferon Cytokine Res. 17 (Suppl. 1), S15-S21.
16. Itri LM, Sherman MI, Palleroni AV, Evans LM, Tran LE, Campion M, Chizzonite R (1989): Incidence and clinical significance of neutralising antibodies in patients receiving recombinant interferon-α2a. J. Interferon Res. 9 (Suppl. 1), S9-S15.
17. Jacobs S, Friedman RM, Nagabhushan, Oden E, Salfi M, Bordens R, Spiegel R (1989): Detection of serum neutralising antibodies to interferon α2b (Intron A) by means of enzyme immunoassay. J. Interferon Res. 9, S292.
18. Kaluz Š, Kabát P, Gibadulinová A, Vojtaššák J, Fuchsberger N, Kontsek P (1994): Interferon α2b is the predominant subvariant detected in human genomic DNAs. Acta Virol. 38, 101-104.
19. Karayianni-Vasconcelos G, Fuchsberger N, Škamlová Z, Kontsek P (1993a): Comparison of antigenic properties of three interferon (IFN)-α2 subvariants and establishment of a quantitative IFN-α2 ELISA. Acta Virol. 37, 509-504.
20. Karayianni-Vasconcelos G, Borecký L, Kontsek P (1993b): Porcine leukocyte interferon exhibits close antigenic relatedness to human interferon α2, but not to human interferon al. Vet. Immunol. Immunopathol. 38, 359-365.
21. Klaus W, Gsell B, Labhardt AM, Senn H (1997): The three-dimensional high resolution structure of human interferon α2a determined by heteronuclear NMR spectroscopy in solution. J. Mol. Biol. 274, 661-675.
22. Kontsek P (1994): Human type I interferons: structure and function. Acta Virol. 38, 345-360.
23. Kontsek P, Borecký L, Kontseková E, Máčiková I, Kolcunová A, Novák M, Krchňák V (1991a): Mapping of two immunodominant structures on human interferon α2c and their role in binding to cells. Mol. Immunol. 28, 1289-1297.
24. Kontsek P, Borecký L, Kontseková E, Máčiková I, Kolcunová A, Novák M, Krchňák V (1991b): Distinct effect of pH 2 on a common antigenic structure found in human interferons-α1 and-α2 in the region 30-35. J. Interferon Res. 11, 327-332.
25. Kúdela O, Kontseková E, Csabayová M, Záhorová K, Kontsek P (1996): Conformational changes in pH 2-treated human interferon-α2 detected with monoclonal antibodies. Hybridoma 15, 185-189.
26. Labdon JE, Gibson KD, Sun S, Pestka S (1984): Some species of human leukocyte interferon are glycosylated. Arch. Biochem. Biophys. 232, 422-426.
27. Larocca AP, Steven CL, Stephen GM, Colby CB, Borden EC (1989): Evaluation of neutralising antibodies in patients treated with recombinant interferon beta. J. Interferon Res. 9, S51-S60
28. Liptáková H, Kontseková E, Fuchsberger N, Oltman M, Stanček D, Kontsek P (1998): Therapy-induced antibodies to interferon-α2a recognise its receptor-binding site. Acta Virol. 42, 279-284.
29. Lok ASF, Lai CL, Leung KY (1990): Interferon antibodies may negate the antiviral effects of recombinant α-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology 11, 1266-1270.
30. McKenna RM, Oberg KE (1997): Antibodies to interferon-a in treated cancer patients: incidence and significance. J. Interferon Cytokine Res. 17, 141-143.
31. Nolte KU, Günther G, von Wussow P (1996). Epitopes recognised by neutralising therapy-induced human anti-interferon-α antibodies are localised within the N-terminal functional domain of recombinant interferon-α2. Eur. J. Immunol. 26, 2155-2159.
32. Oberg K, Alm G (1997): The incidence and clinical significance of antibodies to interferon-α in patients with solid tumors. Biotherapy 10, 1-5.
33. Palleroni AV, Aglione A, Labow M, Brunda MJ, Pestka S, Sinigaglia F, Garotta G, Alsenz J, Braun A (1997): Interferon immunogenicity: preclinical evaluation of interferon-α2A. J. Interferon Cytokine Res. 17 (Suppl. 1), S23-S27.
34. Porres JC, Carreno V, Ruiz M, Marron JA, Bartolom J (1989): Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. Hepatology 8, 351-357.
35. Radhakrishnan R, Walter LJ, Hruza A, Reichert P, Trotta PP, Nagabhushnan TL, Walter MR (1996): Zinc mediated dimer of human interferon-α2b revealed by X-ray crystallography. Structure 4, 1453-1463.
36. Russo D, Candoni A, Zuffa E, Minisini R, Silvestri F, Fanin F, Zaja F, Martinelli G, Tura S, Botta G, Baccarani M (1996): Neutralising anti-interferon α antibodies and response to treatment in patients with Ph+ chronic myeloid leukemia sequentialy treated with recombinant and lymphoblastoid interferon α. Br. J. Haematol. 94, 300-305.
37. Schmahling C, Schneider FJ (1992): Low incidence of antibody formation due to long-term interferon-α2c treatment of cancer patients. Clin. Investig. 70, 136-141.
38. Senda T, Saitoh S, Mitsui Y (1995): Refined crystal structure of recombinant murine interferon-beta at 2.15Å resolution. J. Mol. Biol. 253, 187-207.
39. Siemers R, Hensley L, Ozer H (1988): Localization of the receptor binding site of IFN-α2b. J. Immunol. 141, 1550-1555.
40. Steinmann GG, God B, Rosenkaimer F, Adolf G, Bidlingmaier G, Frühbeis B, Lamche H, Linder J, Patzelt E, Steis RG, Smith JW, Urba WJ, Clark JW, Itri LM, Evans LM, Schoenberger C, Longo DL (1988): Resistance to recombinant interferon α2a in hairy cell leukemia associated with neutralising anti-interferon antibodies. N. Engl. J. Med. 318, 1409-1413.
41. Week PK, Leventhal BG, Brand C, Finter NB (1989): Detection and incidence of neutralising antibodies to interferon-α-n1. J. Interferon Res. 9 (Suppl. 1), S37-S43.
42. Wussow von P, Jakschies D, Freund M, Deicher H (1989): Humoral response to recombinant interferon-(2b in patients receiving recombinant interferon-α2b therapy. J. Interferon Res. 9 (Suppl. 1), S25-S31.
43. Wussow von, PV, Jakschies D, Freund M, Hehlmann H, Brockhaus F, Hochkeppel H, Horisberg M, Deicher H (1991a): Treatment of antirecombinant interferon a2 antibody positive CML patients with natural interferon a. Br. J. Haematol. 78, 210-216.
44. Wussow von, PV, Pralle J, Hochkeppel HK, Jakschies D, Sonnen S, Schmidt H, Muller-Rosenau D, Franke M, Haferlach T, Ywingers T, Rapp U, Deicher H (1991b): Effective natural interferon-α therapy in recombinant interferon-α resistant patients with hairy cell leukemia. Blood 78, 38-43.
45. Wussow von, PV, Heimann R, Hochhaus T, Jakschies D, Nolte KU, Prümmer O, Ansari H, Hasford J, Heimpel H, Deicher H (1994): Roferon (rIFN-α2a) is more immunogenic than Intron A (rIFN-α2b) in patients with chronic myelogenous leukemia. J. Interferon Res. 14, 217-219.